| Ytd | 31.80% | |
| 1y | 10.80% |
| Open | 15.26 | Prev Close | 15.51 | Low | 14.80 | High | 15.50 | Mkt Cap | 1.64B |
| Vol | 362.43K | Avg Vol | 2.86M | EPS | -5.67 | P/E | -2.74 | Forward P/E | -7.97 |
| Beta | 1.28 | Short Ratio | 5.15 | Inst. Own | 91.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 12.55 | 200-d Avg | 11.65 | 1yr Est | 21.94 |
BHVN News
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combina
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga
Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets.
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper
BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomark
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addres
Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-Ig
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), t
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for
That pundit flagged the stock as a buy. He also expects it to more than double in price.
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, accor
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in th
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-e
Biohaven Ltd. (NYSE: BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy"
During Wednesday's morning trading, 125 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday